Effects of somatostatin on plasma glucose and glucagon levels in human diabetes mellitus. Pathophysiologic and therapeutic implications.

No abstract is available for this paper.

• Publication year

  1974

• Venue

  New England Journal of Medicine

• Publication date

  1974-09-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJM197409122911102PMID 4604408
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Acute suppression of insulin and glucose levels by synthetic somatostatin in normal human subjects.

  1974cited by this paper
• Inhibition by somatostatin on the release of TSH induced in man by thyrotropin-releasing factor.

  1974cited by this paper
• Effect of somatostatin in patients with acromegaly: suppression of growth hormone, prolactin, insulin and glucose levels.

  1974cited by this paper
• Somatostatin: Hypothalamic Inhibitor of the Endocrine Pancreas

  1974cited by this paper
• Lack of Glucagon Response to Hypoglycemia in Diabetes: Evidence for an Intrinsic Pancreatic Alpha Cell Defect

  1973cited by this paper
• Evaluation of alpha-cell function by infusion of alanine in normal, diabetic and obese subjects.

  1973cited by this paper
• Action of growth-hormone-release inhibitory hormone in healthy men and in acromegaly.

  1973cited by this paper
• Inhibition of growth hormone release in humans by somatostatin.

  1973cited by this paper
• Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone

  1973cited by this paper
• [Solid-phase total synthesis of a tetradecapeptide having the chemical and biological properties of somatostatine].

  1973cited by this paper
• Abnormal Alpha Cell Function in Diabetics Response to Insulin

  1972cited by this paper
• Abnormalities of glucagon metabolism in untreated diabetes mellitus.

  1972cited by this paper
• Determination of pancreatic and gut Glucagon-Like Immunoreactivity (GLI) in normal and diabetic subjects

  1972cited by this paper
• Glucagon physiology and pathophysiology.

  1971cited by this paper
• Studies of pancreatic alpha cell function in normal and diabetic subjects.

  1970cited by this paper
• Carbohydrate homeostasis.

  1970cited by this paper
• Carbohydrate homeostasis. I.

  1970cited by this paper
• Role of insulin in the hepatic handling of glucose.

  1969cited by this paper

• Roger Guillemin (1924–2024) : un neuro-endocrinologue franco-américain nobélisé, inventeur de la somatostatine

  2024cites this paper
• 100 years of glucagon and 100 more

  2023cites this paper
• Metabolic Messengers: glucagon

  2023cites this paper
• The human α cell in health and disease.

  2023cites this paper
• Treatment of Type 2 Diabetes in Youth

  2023cites this paper
• Retatrutide: a triple incretin receptor agonist for obesity management

  2023cites this paper
• ZT‐01: A novel somatostatin receptor 2 antagonist for restoring the glucagon response to hypoglycaemia in type 1 diabetes

  2022cites this paper
• The past, present, and future physiology and pharmacology of glucagon.

  2022cites this paper
• Glucagon's Metabolic Action in Health and Disease.

  2021cites this paper
• Revisiting the Pharmacological Value of Glucagon: An Editorial for the Special Issue “The Biology and Pharmacology of Glucagon”

  2020cites this paper
• Pituitary and Extrapituitary Effects of Somatostatin in Normal Man

  2020cites this paper
• Role of Somatostatin in the Regulation of Central and Peripheral Factors of Satiety and Obesity

  2020cites this paper
• Conceptualization of a Parasympathetic Endocrine System

  2019cites this paper
• Glucagon-like peptide 1 (GLP-1)

  2019cites this paper
• Predictive factors of posttransplant glucose intolerance in Japanese patients with type 1 diabetes after pancreas transplantation.

  2019cites this paper
• Anti-Obesity Therapy: from Rainbow Pills to Polyagonists

  2018influential citation
• Problem or solution: The strange story of glucagon

  2018cites this paper
• A first‐in‐human pharmacodynamic and pharmacokinetic study of a fully human anti‐glucagon receptor monoclonal antibody in normal healthy volunteers

  2017cites this paper
• The New Biology and Pharmacology of Glucagon.

  2017cites this paper
• Glucagon in Islet and Metabolic Regulation

  2016cites this paper
• Glucagon orchestrates stress‐induced hyperglycaemia

  2016cites this paper
• Pharmacological Actions of Glucagon-Like Peptide-1, Gastric Inhibitory Polypeptide, and Glucagon.

  2016cites this paper
• Glucagon--Early breakthroughs and recent discoveries.

  2015cites this paper
• New Endocrinology of the Brain

  2015cites this paper
• Physiological and pathophysiological control of glucagon secretion by pancreatic α-cells

  2015cites this paper
• G protein-coupled receptors as regulators of glucose homeostasis and therapeutic targets for diabetes mellitus.

  2014cites this paper
• Paracrine regulation of glucagon secretion from pancreatic islets

  2014cites this paper
• Ligand-Directed AAVP to Deliver a Therapeutic Transgene to Neuroendocrine Tumors of the Pancreas

  2013cites this paper
• Chronic treatment with a glucagon receptor antagonist lowers glucose and moderately raises circulating glucagon and glucagon-like peptide 1 without severe alpha cell hypertrophy in diet-induced obese mice

  2011cites this paper
• Function and expression of somatostatin receptors of the endocrine pancreas.

  2008cites this paper
• Effect of intravenous infusion of somatostatin on gastric, pancreatic and biliary secretion in the rat

  2007cites this paper
• Effect of a somatostatin analog on insulin requirement and hormone levels in 6 insulin-dependent juvenile-onset diabetics subjected to artificial pancreas

  2007cites this paper
• Maintenance of the postabsorptive plasma glucose concentration: insulin or insulin plus glucagon?

  2005cites this paper
• Differing postnatal development of the somatostatin- and luliberin- systems in the male and female rat

  2004cites this paper
• Increased plasma levels of plasminogen activator inhibitor-1 and soluble vascular cell adhesion molecule after triacylglycerol infusion in man

  2003cites this paper
• Use of somatostatin receptor ligands in obesity and diabetic complications.

  2002cites this paper
• The Circulating Hormonal Milieu of the Endocrine Pancreas in Healthy Individuals, Organ Donors, and the Isolated Perfused Human Pancreas

  2000cites this paper
• Insulin secretory capacity and the regulation of glucagon secretion in diabetic and non-diabetic alcoholic cirrhotic patients.

  1998cites this paper
• The roles of insulin and glucagon in the regulation of hepatic glycogen synthesis and turnover in humans.

  1996cites this paper
• New hypoglycaemic agents.

  1994cites this paper
• Octreotide inhibits insulin-like growth factor-I hepatic gene expression in the hypophysectomized rat: evidence for a direct and indirect mechanism of action.

  1992cites this paper
• New Pharmacological Approaches to Therapy of NIDDM

  1992cites this paper
• [Insulin/glucagon relationship in spontaneous diabetic remission].

  1991cites this paper
• Low-dose octreotide is able to cause a maximal inhibition of the glycemic responses to a mixed meal in obese type 2 diabetic patients treated with insulin.

  1991cites this paper
• A Case of Cervical Carcinoma of the Uterus Presenting with Hyperosmolar Non‐ketotic Coma as a Manifestation of Ectopic Adrenocorticotropic Hormone Syndrome

  1991cites this paper
• Effect of a long-acting somatostatin analogue (BIM23014) on proliferative diabetic retinopathy: A pilot study

  1991cites this paper
• The Use of Continuous Subcutaneous Octreotide Infusion in Brittle Type 1 Diabetic Patients

  1991cites this paper
• Role of Glucose, Insulin, and Glucagon in Glycogen Mobilization in Human Hepatocytes

  1991cites this paper
• Chapter 22. New Approaches to Diabetes

  1990cites this paper
• Growth Factors and Diabetic Complications

  1990cites this paper
• Abnormal Glucagon Secretion in Type 2 (Noninsulin-Dependent) Diabetes Mellitus: Causes and Consequences

  1989cites this paper
• Somatostatin Ve Diabet

  1989cites this paper
• Effects of a somatostatin derivative (SMS 201–995) on postprandial hyperglycemia in insulin-dependent diabetics studied by means of a closed-loop device

  1989cites this paper
• Somatostatin Analogues in Diabetes Mellitus

  1989cites this paper
• Somatostatin in portal hypertension

  1989cites this paper
• Assessment of Pancreatic Islet‐Cell Population in the Hyperglycemic Athymic Nude Mouse: Immunohistochemical, Ultrastructural, and Hormonal Studies

  1989cites this paper
• Metabolic Effects of Long-Acting Somatostatin Analogue (Sandostatin) in Type I Diabetic Patients on Conventional Therapy

  1989cites this paper
• Somatostatin and its analogues in the therapy of gastrointestinal disease.

  1989cites this paper
• Regulatory peptides, the hypothalamus and diabetes

  1989cites this paper
• Temporal study of metabolic change when poorly controlled noninsulin-dependent diabetics change from low to high carbohydrate and fiber diet.

  1988cites this paper
• Glucagon and glucose tolerance in liver cirrhosis.

  1988cites this paper
• The effects of the somatostatin analogue SMS 201-995 on carbohydrate homeostasis of insulin-dependent diabetics as assessed by the artificial endocrine pancreas.

  1988cites this paper
• Somatostatin reduces posthypoglycemic insulin resistance in insulin-dependent diabetes mellitus.

  1988cites this paper
• Prevention of the Dawn phenomenon (early morning hyperglycemia) in insulin-dependent diabetes mellitus by bedtime intranasal administration of a long-acting somatostatin analog.

  1988cites this paper
• [Does somatostatin have a role in the treatment of diabetes?].

  1988cites this paper
• Effect of a new long-acting somatostatin analogue (SMS 201–995) on glycemic and hormonal profiles in insulin-treated type II diabetic patients

  1988cites this paper
• Reversal of somatostatin inhibition of AVP-induced cAMP by pertussis toxin.

  1988cites this paper
• noninsulin-dependent diabetics change from low to high carbohydrate and fiber diet13

  1988cites this paper
• Importance of glucagon in the control of futile cycling as studied in alloxan-diabetic dogs

  1987cites this paper
• Hyperglucagonemia and insulin-mediated glucose metabolism.

  1987cites this paper
• Suppression of growth hormone and somatomedin C by long-acting somatostatin analog SMS 201-995 in type I diabetes mellitus.

  1987cites this paper
• Effects of highly potent octapeptide analogs of somatostatin on growth hormone, insulin and glucagon release.

  1987cites this paper
• Hypoglycaemic agents which do not release insulin.

  1987cites this paper
• Somatostatin analog SMS 201-995 and insulin needs in insulin-dependent diabetic patients studied by means of an artificial pancreas.

  1986cites this paper
• Effect of the Long-Acting Somatostatin Analogue SMS 201-995 on the Glycaemic Control in Insulin-Treated Diabetics

  1986cites this paper
• Non-pituitary actions of somatostatin. A review on the therapeutic role of SMS 201-995 (sandostatin).

  1986cites this paper
• Hepatic Glucagon Clearance During Insulin Induced Hypoglycemia

  1986cites this paper
• Somatostatin: a peptide with unexpected physiologic activities.

  1986cites this paper
• Histology, Cell Types, and Functional Correlation of Islets of Langerhans

  1985cites this paper
• Capillary orientation of rat pancreatic D-cell processes: evidence for endocrine release of somatostatin.

  1985cites this paper
• Gastroenteropancreatic endocrine tumors

  1985cites this paper
• Reduced Postprandial Hyperglycemia After Subcutaneous Injection of a Somatostatin-Analogue (SMS 201-995) in Insulin-dependent Diabetes Mellitus

  1985cites this paper
• Reduced Inhibitory Effect of Somatostatin on the Exocrine Function of the Pancreas and on Serum Insulin (IRI) Levels in Chronic Relapsing Pancreatitis

  1984cites this paper
• [Biologically active peptides: known compounds--new aspects. 2: Functions--general principles].

  1984cites this paper
• Glucagon and Liver Glucose Output In Vivo

  1983cites this paper
• Effects of a long-acting somatostatin analogue on postprandial hyperglycemia in insulin-dependent diabetes mellitus.

  1983cites this paper
• Immunoreactive somatostatin in two pulmonate gastropods.

  1983cites this paper
• Pharmacologic Compounds Affecting Glucagon Secretion

  1983cites this paper
• Glucagon suppression improves glucoregulation in moderate but not chronic severe diabetes.

  1983cites this paper
• The Metabolic Clearance Rate of Glucagon

  1983cites this paper
• Effects of cyclic somatostatin on insulin, C-peptide and immunoreactive glucagon response to oral glucose loading in obese patients.

  1982cites this paper
• Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist.

  1982cites this paper
• The Psychophysiologic Aspects of Stress in Juvenile Diabetes Mellitus

  1982cites this paper
• Labiele en stabiele insuline-afhankelijke (type 1) diabetes mellitus

  1982cites this paper
• The in vivo metabolism of somatostatin 28: possible relationship between diminished metabolism and enhanced biological action.

  1982cites this paper
• Somatostatin-28 is longer acting and more selective than somatostatin-14 on pituitary and pancreatic hormone release.

  1982cites this paper
• [Immunohistochemical demonstration of somatostatin-28 like immunoreactivity in the fetal and adult human gut and pancreas].

  1982cites this paper
• Somatostatin-28 like immunoreactivity in normal and tumour tissue from duodenum and pancreas.

  1982cites this paper
• Effect of somatostatin on vasopressin-induced antidiuresis and renal cyclic AMP of rats.

  1982cites this paper
• Effects of somatostatin in a case of severe hypoglycemia due to nesidioblastosis

  1981cites this paper